Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Tularik Inc. (TLRK) -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (174)	4/19/2002 7:32:57 PM
From: scaram(o)uche	Respond to of 598

Just listened to it. This is something like what I was expecting. The shorts (1) have grabbed onto something irrelevant, and (2) don't understand that pharmas only wish that they could garner a TLRK-like hunk of medicine's future for $500M. Why do you file abstracts on negative data? Clinical investigators are scientists. It's what scientists do, and no DECENT company will ask their clinical investigators to hold onto data. It's another piece of valuable information, for those who might wander the path in the future, re. tubulin binders and lung Ca. If anyone thinks that paclitaxel does much for lung Ca, speak up! First of the new INDs at mid-year. T67 HCC phase III launched by 1Q 2003. I encourage everyone to listen to the call.